enVVeno Medical Corp 8-K

What Happened
enVVeno Medical Corporation announced on February 4, 2026 (via a Form 8-K) that it had approximately $28 million in cash and investments as of December 31, 2025, and that it has regained compliance with the minimum bid price requirement and all other criteria for continued listing on The NASDAQ Stock Market. The company issued a press release on the same date (Exhibit 99.1).

Key Details

• Report date: February 4, 2026 (Form 8-K filing).
• Cash and investments: approximately $28 million as of December 31, 2025.
• Listing status: regained compliance with NASDAQ minimum bid price requirement and all other continued-listing criteria.
• Press release referenced and furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters
Regaining NASDAQ compliance removes the immediate risk of delisting, preserving the company’s trading status, liquidity and access to public capital markets. The disclosed cash and investments balance gives investors a snapshot of enVVeno’s year‑end liquidity position; the filing did not report revenue or earnings figures. Together, these facts are material to shareholders evaluating near‑term listing stability and the company’s financial resources.